Societal Costs of Haemophilia A (HMA)

Laurie Brown, Hai Anh La, Jinjing Li

Research output: Book/ReportReports


BACKGROUND: In Australia, haemophilia A (HMA) occurs in over 2,200 adults and children, with varied disease severity. Between 60% and 80% of people with HMA report at least one bleeding episode annually; most commonly affecting the joints, muscles and/or soft tissue. People with HMA require lifetime intravenous treatment with recombinant or plasma derived Factor VIII (FVIII) or bypassing agents (BPAs); disease severity and FVIII inhibitor status determining the treatment regimes.

AIM: To identify and quantify direct and indirect societal and economic costs of HMA in Australia under current treatment practices. METHODS: Using a cost of illness approach, direct costs were defined as the cost of ‘resources’ expended on people with HMA, including health care and related support or non-medical expenses (out-of-pocket costs for individuals, their family or carers) and government support payments. Indirect costs are defined as value of lost productivity by people with HMA or their carers, potentially impacting on superannuation accumulation, reduced savings and personal or family assets, as well as reduced income tax revenue for Government.

RESULTS: Treatment costs (FVIII blood products and BPAs) were estimated to be $84.5 million or an average of $91,282 per patient per year, contributing to 87% of direct costs and 76% of total costs. Indirect costs contributed to $14.3 million or an annual cost per patient of $15,425, and 12.9% of total costs. Lost productivity accounted for 56% of all indirect costs. Overall, the total cost of moderate and severe HMA in Australia in 2018 was estimated to be $111.1 million; or an average annual cost of $119,956 per patient.

CONCLUSIONS Consistent with other reported studies, the cost of blood products (including BPAs) dominated expenditure, representing 76.1% of total annual costs. The second highest cost, lost productivity, highlights the need for new treatments that improve quality of life and workforce participation.
Original languageEnglish
Place of PublicationCanberra
Commissioning bodyRoche Australia
Number of pages127
Publication statusPublished - 30 Jul 2019


Dive into the research topics of 'Societal Costs of Haemophilia A (HMA)'. Together they form a unique fingerprint.

Cite this